Invasive lobular carcinoma of the breast: Should this be regarded as a chronic disease?

被引:13
作者
Anwar, I. F. [1 ]
Down, S. K. [1 ]
Rizvi, S. [1 ]
Farooq, N. [1 ]
Burger, A. [1 ]
Morgan, A. [1 ]
Hussien, M. I. [1 ]
机构
[1] Norfolk & Norwich Univ Hosp, Breast Surg Unit, Norwich NR4 7UP, Norfolk, England
关键词
Breast cancer; Lobular; Breast conservation surgery; Local recurrence; DUCTAL CARCINOMA; MAMMOGRAPHIC FINDINGS; CANCER; PATTERNS; FEATURES; THERAPY; RECURRENCE; STAGE; CHEMOTHERAPY; MASTECTOMY;
D O I
10.1016/j.ijsu.2010.04.003
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The surgical treatment of patients with invasive lobular carcinoma is still controversial due to its different clinical and pathological features. Most studies report local recurrence after relatively short follow-up periods, which is usually 5 years. However there is some evidence to suggest that local recurrence may occur late in the course of follow-up. Aim of the study: To study the implications and outcome of extending the follow-up period of patients treated for invasive lobular carcinoma. Patients and methods: Patients (268) treated between 1989 and 1996 were reviewed. Thirty-three patients were excluded as they had primary hormonal therapy. The outcomes for 235 patients were analyzed. Results: Seventy-nine patients (33.6%) had breast conservation surgery (group I), which was followed by re-excision due to positive margins in 23 patients (29%), and 156 patients (66.3%) had mastectomy (group II). Compared to group II, tumours in group I were smaller (mean size17 vs. 37 mm, P = 0.001), multifocal [20 (25%) vs. 14 (9%), P = 0.003] and with more positive margins [23 (29%) vs. 24 (15%), P = 0.0009]. Only 33 patients (21%) in group II, and all patients in group I had post-operative radiotherapy (P = 0.0001). Forty-eight patients (17.9%) developed local recurrence [27 (34%) in group I and 21 (13.4%) in group II, P = 0.0005] after a median follow-up period of 167.8 months. The mean time to local recurrence was 127 (range 24-196) months. Univariate analysis showed that the type of surgery, margin status, adjuvant radiotherapy and chemotherapy significantly affected local recurrence (P = 0.0005, 0.02, 0.04 and 0.05 respectively). Cox regression analysis showed that the only factor affected local recurrence was the type of surgery (relative risk 2.43, 95% confidence interval 1.22-4.83, P = 0.01) The overall survival was 99.3 months (78.2%). Univariate and Cox regression analyses showed that only the patients age at diagnosis significantly affected survival (P = 0.003). Conclusion: Local recurrence may be a late event in patients treated for invasive lobular carcinoma of the breast and extended follow-up may be considered. In this study mastectomy offers better local control. (C) 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:346 / 352
页数:7
相关论文
共 52 条
[1]  
ADAMI HO, 1985, CANCER-AM CANCER SOC, V56, P898, DOI 10.1002/1097-0142(19850815)56:4<898::AID-CNCR2820560433>3.0.CO
[2]  
2-L
[3]  
[Anonymous], 1982, AM J CLIN PATHOL, V78, P806, DOI [DOI 10.1093/AJCP/78.6.806, 10.1093/ajcp/78.6.806]
[4]   Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome [J].
Arpino, G ;
Bardou, VJ ;
Clark, GM ;
Elledge, RM .
BREAST CANCER RESEARCH, 2004, 6 (03) :R149-R156
[5]  
ASHIKARI R, 1973, CANCER, V31, P110, DOI 10.1002/1097-0142(197301)31:1<110::AID-CNCR2820310115>3.0.CO
[6]  
2-V
[7]  
BAKER RR, 1990, SURG CLIN N AM, V70, P963
[8]  
BORST MJ, 1993, SURGERY, V114, P637
[9]   MAMMOGRAPHIC FEATURES OF INVASIVE LOBULAR AND INVASIVE DUCTAL CARCINOMA OF THE BREAST - A COMPARATIVE-ANALYSIS [J].
CORNFORD, EJ ;
WILSON, ARM ;
ATHANASSIOU, E ;
ELLIS, IO ;
ELSTON, CW ;
BLAMEY, RW .
BRITISH JOURNAL OF RADIOLOGY, 1995, 68 (809) :450-453
[10]   Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes [J].
Cristofanilli, M ;
Gonzalez-Angulo, A ;
Sneige, N ;
Kau, SW ;
Broglio, K ;
Theriault, RL ;
Valero, V ;
Buzdar, AU ;
Kuerer, H ;
Buccholz, TA ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :41-48